{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:45:58Z","timestamp":1790660758680,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3502000"],"award-info":[{"award-number":["2022YFC3502000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82174229"],"award-info":[{"award-number":["82174229"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obesity Pillars"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.obpill.2025.100162","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T03:33:01Z","timestamp":1738207981000},"page":"100162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials"],"prefix":"10.1016","volume":"13","author":[{"given":"Haoyang","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghua","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yexuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyuan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingshan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lujin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.obpill.2025.100162_bib1","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.fertnstert.2017.02.104","article-title":"Obesity pandemic: causes, consequences, and solutions-but do we have the will?","volume":"107","author":"Meldrum","year":"2017","journal-title":"Fertil Steril"},{"issue":"8","key":"10.1016\/j.obpill.2025.100162_bib2","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1517\/17460441.2015.1044966","article-title":"Latest approaches for the treatment of obesity","volume":"10","author":"Jackson","year":"2015","journal-title":"Expet Opin Drug Discov"},{"issue":"1","key":"10.1016\/j.obpill.2025.100162_bib3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jacc.2017.11.011","article-title":"Obesity: pathophysiology and management","volume":"71","author":"Gadde","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.obpill.2025.100162_bib4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s13679-015-0169-4","article-title":"Overweight and obesity: prevalence, consequences, and causes of a growing public health problem","volume":"4","author":"Williams","year":"2015","journal-title":"Current obes report"},{"issue":"1","key":"10.1016\/j.obpill.2025.100162_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health effects of overweight and obesity in 195 countries over 25 years","volume":"377","author":"Afshin","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.obpill.2025.100162_bib6","series-title":"Obesity","year":"2021"},{"issue":"12","key":"10.1016\/j.obpill.2025.100162_bib7","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s11883-014-0457-6","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"16","author":"Johnston","year":"2014","journal-title":"Curr Atherosclerosis Rep"},{"issue":"0 2","key":"10.1016\/j.obpill.2025.100162_bib8","first-page":"S1","article-title":"Challenging obesity: patient, provider, and expert perspectives on the roles of available and emerging nonsurgical therapies","volume":"23","author":"Apovian","year":"2015","journal-title":"Obesity (Silver Spring, Md)"},{"issue":"2","key":"10.1016\/j.obpill.2025.100162_bib9","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: an endocrine Society clinical practice guideline","volume":"100","author":"Apovian","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"1","key":"10.1016\/j.obpill.2025.100162_bib10","first-page":"149","article-title":"Best practices in the management of overweight and obesity","volume":"105","author":"Tchang","year":"2021","journal-title":"Med Clin"},{"issue":"9548","key":"10.1016\/j.obpill.2025.100162_bib11","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet (London, England)"},{"issue":"6","key":"10.1016\/j.obpill.2025.100162_bib12","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1210\/jc.2003-030049","article-title":"Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes","volume":"88","author":"Meier","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"1\u20132","key":"10.1016\/j.obpill.2025.100162_bib13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.2040-1124.2010.00022.x","article-title":"GIP and GLP-1, the two incretin hormones: similarities and differences","volume":"1","author":"Seino","year":"2010","journal-title":"J\u00a0diabetes invest"},{"issue":"2","key":"10.1016\/j.obpill.2025.100162_bib14","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1152\/physrev.00013.2014","article-title":"Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease","volume":"95","author":"Sandoval","year":"2015","journal-title":"Physiol Rev"},{"key":"10.1016\/j.obpill.2025.100162_bib15","article-title":"Pharmacotherapy of obesity: an update on the available medications and drugs under investigation","volume":"58","author":"Chakhtoura","year":"2023","journal-title":"EClinMedicine"},{"issue":"11","key":"10.1016\/j.obpill.2025.100162_bib16","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s40265-022-01746-8","article-title":"Tirzepatide: first approval","volume":"82","author":"Syed","year":"2022","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.obpill.2025.100162_bib17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.tcm.2021.12.008","article-title":"Semaglutide for the treatment of obesity","volume":"33","author":"Chao","year":"2023","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.obpill.2025.100162_bib18","article-title":"GLP-1 receptor agonists for the treatment of obesity: role as a promising approach","volume":"14","author":"Wang","year":"2023","journal-title":"Front Endocrinol"},{"issue":"9","key":"10.1016\/j.obpill.2025.100162_bib19","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/13543776.2023.2274905","article-title":"An updated patent review of GLP-1 receptor agonists (2020-present)","volume":"33","author":"Lu","year":"2023","journal-title":"Expert Opin Ther Pat"},{"issue":"3","key":"10.1016\/j.obpill.2025.100162_bib20","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/clpt.2012.122","article-title":"Model-based meta-analysis: an important tool for making quantitative decisions during drug development","volume":"92","author":"Mould","year":"2012","journal-title":"Clin Pharmacol Therapeut"},{"key":"10.1016\/j.obpill.2025.100162_bib21","first-page":"l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clinical research ed)"},{"issue":"11","key":"10.1016\/j.obpill.2025.100162_bib22","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1080\/13543784.2023.2283020","article-title":"Retatrutide showing promise in obesity (and type 2 diabetes)","volume":"32","author":"Doggrell","year":"2023","journal-title":"Expet Opin Invest Drugs"},{"key":"10.1016\/j.obpill.2025.100162_bib23","article-title":"Obesity management for the treatment of type 2 diabetes: emerging evidence and therapeutic approaches","volume":"27","author":"Morissette","year":"2024","journal-title":"J\u00a0Pharm Pharmaceut Sci : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques"},{"key":"10.1016\/j.obpill.2025.100162_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101090","article-title":"Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease","volume":"46","author":"Baggio","year":"2021","journal-title":"Mol Metabol"},{"issue":"9","key":"10.1016\/j.obpill.2025.100162_bib25","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1139\/apnm-2012-0441","article-title":"Effects of age, sex, and treatment on weight-loss dynamics in overweight people","volume":"38","author":"Rojo-Tirado","year":"2013","journal-title":"Appl Physiol, Nutr and Metab = Physiologie appliquee, nutrition et metabolisme"},{"key":"10.1016\/j.obpill.2025.100162_bib26","first-page":"23","volume":"vol. 38","author":"Jura","year":"2016"},{"key":"10.1016\/j.obpill.2025.100162_bib27","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/191209","article-title":"Baseline obesity status modifies effectiveness of adapted diabetes prevention program lifestyle interventions for weight management in primary care","volume":"2013","author":"Azar","year":"2013","journal-title":"BioMed Res Int"},{"issue":"17","key":"10.1016\/j.obpill.2025.100162_bib28","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1161\/CIRCULATIONAHA.111.028381","article-title":"Food and drug administration's obesity drug guidance document: a short history","volume":"125","author":"Colman","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.obpill.2025.100162_bib29","series-title":"FDA drug safety communication","year":"2020"},{"key":"10.1016\/j.obpill.2025.100162_bib30","doi-asserted-by":"crossref","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity","author":"Drucker","year":"2024","journal-title":"Diabetes Care"},{"issue":"3\u20134","key":"10.1016\/j.obpill.2025.100162_bib31","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos","year":"2014","journal-title":"Rev Diabet Stud : Reg Dev Stud"},{"issue":"7","key":"10.1016\/j.obpill.2025.100162_bib32","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1007\/s00125-014-3231-y","article-title":"Risk of pancreatitis in patients treated with incretin-based therapies","volume":"57","author":"Meier","year":"2014","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.obpill.2025.100162_bib33","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/dom.12926","article-title":"Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials Diabetes","volume":"19","author":"Monami","year":"2017","journal-title":"Obes Metabol"},{"issue":"3","key":"10.1016\/j.obpill.2025.100162_bib34","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1016\/j.diabres.2013.11.014","article-title":"Severe acute renal failure in patients treated with glucagon-like peptide-1 receptor agonists","volume":"103","author":"Dubois-Laforgue","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"10.1016\/j.obpill.2025.100162_bib35","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1463-1326.2011.01357.x","article-title":"An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future Diabetes","volume":"13","author":"Madsbad","year":"2011","journal-title":"Obes Metabol"}],"container-title":["Obesity Pillars"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368125000063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368125000063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T23:22:15Z","timestamp":1762644135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667368125000063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":35,"alternative-id":["S2667368125000063"],"URL":"https:\/\/doi.org\/10.1016\/j.obpill.2025.100162","relation":{},"ISSN":["2667-3681"],"issn-type":[{"value":"2667-3681","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials","name":"articletitle","label":"Article Title"},{"value":"Obesity Pillars","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.obpill.2025.100162","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of Obesity Medicine Association.","name":"copyright","label":"Copyright"}],"article-number":"100162"}}